PHARMACY POLICY STATEMENT
Ohio Medicaid

<table>
<thead>
<tr>
<th>DRUG NAME</th>
<th>Mepsevii (vestronidase alfa-vjbk)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BILLING CODE</td>
<td>J3397</td>
</tr>
<tr>
<td>BENEFIT TYPE</td>
<td>Medical</td>
</tr>
<tr>
<td>SITE OF SERVICE ALLOWED</td>
<td>Home/Office/Outpatient</td>
</tr>
<tr>
<td>STATUS</td>
<td>Prior Authorization Required</td>
</tr>
</tbody>
</table>

Mepsevii is an enzyme replacement therapy (ERT) that was approved by the FDA in 2017 for the treatment of Sly Syndrome, also known as mucopolysaccharidosis type VII (MPS VII). MPS VII is a very rare, progressive inborn error of metabolism. Mutations of the GUSB gene cause deficiency of the enzyme beta glucuronidase. Normally this lysosomal enzyme breaks down glycosaminoglycans (GAGs) (previously known as mucopolysaccharides) but when reduced in MPS VII, the GAG substrates heparan sulfate (HS), dermatan sulfate (DS), and chondroitin sulfate (CS) accumulate throughout the body causing cellular and organ dysfunction. A distinguishing clinical feature of MPS VII is the presence of hydrops fetalis (excess accumulation of fluids in the body) in severe phenotypes.

Mepsevii (vestronidase alfa-vjbk) will be considered for coverage when the following criteria are met:

**Sly Syndrome (Mucopolysaccharidosis VII or MPS VII)**

For *initial* authorization:
1. Medication must be prescribed by or in consultation with a geneticist, metabolic specialist, or pediatrician experienced with managing mucopolysaccharidoses; AND
2. Member has a diagnosis of MPS VII confirmed by at least one of the following:
   a) Low beta-glucuronidase (GUS) enzyme activity, and/or
   b) Molecular genetic testing reveals pathogenic mutation of the GUSB gene; AND
3. Member has elevated urinary glycosaminoglycan (uGAG) excretion at a minimum of 2-fold over the mean normal for age.
4. **Dosage allowed/Quantity limit:** 4 mg/kg administered by intravenous infusion every two weeks

*If all the above requirements are met, the medication will be approved for 6 months.*

For *reauthorization*:
1. Chart notes must show reduced uGAG excretion level; AND
2. Improvement or stabilization of at least one of the following compared to baseline: six-minute walk test (6MWT), forced vital capacity (FVC), motor function, visual acuity, hepatosplenomegaly, or fatigue.

*If all the above requirements are met, the medication will be approved for an additional 12 months.*

CareSource considers Mepsevii (vestronidase alfa-vjbk) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.

OH-MED-P-366685
<table>
<thead>
<tr>
<th>DATE</th>
<th>ACTION/DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>09/13/2018</td>
<td>New policy for Mepsevii created.</td>
</tr>
<tr>
<td>07/27/2021</td>
<td>Transferred to new template. Updated J code. Added home and office to sites of service. Updated references. Added specialist requirement. Clarified diagnosis requirement. Removed baseline multi domain testing. Changed initial approval duration from 12 months to 6 months. Edited renewal criteria to reflect efficacy results from clinical trials. Removed bone marrow/stem cell transplant exclusion.</td>
</tr>
</tbody>
</table>

References:


Effective date: 01/01/2022
Revised date: 07/27/2021